SG11201807223UA - CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC) - Google Patents

CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Info

Publication number
SG11201807223UA
SG11201807223UA SG11201807223UA SG11201807223UA SG11201807223UA SG 11201807223U A SG11201807223U A SG 11201807223UA SG 11201807223U A SG11201807223U A SG 11201807223UA SG 11201807223U A SG11201807223U A SG 11201807223UA SG 11201807223U A SG11201807223U A SG 11201807223UA
Authority
SG
Singapore
Prior art keywords
new york
international
cancer cell
hmsc
rule
Prior art date
Application number
SG11201807223UA
Other languages
English (en)
Inventor
Ira S Cohen
Peter R Brink
Michael R Rosen
Original Assignee
Univ Columbia
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Univ New York State Res Found filed Critical Univ Columbia
Publication of SG11201807223UA publication Critical patent/SG11201807223UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201807223UA 2016-03-23 2017-03-23 CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC) SG11201807223UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312230P 2016-03-23 2016-03-23
PCT/US2017/023803 WO2017165641A1 (en) 2016-03-23 2017-03-23 CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Publications (1)

Publication Number Publication Date
SG11201807223UA true SG11201807223UA (en) 2018-09-27

Family

ID=59900921

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807223UA SG11201807223UA (en) 2016-03-23 2017-03-23 CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)

Country Status (10)

Country Link
US (1) US20200171067A1 (zh)
EP (1) EP3432714A4 (zh)
JP (1) JP2019509297A (zh)
KR (1) KR20180123052A (zh)
CN (1) CN108882705A (zh)
AU (2) AU2017238505B2 (zh)
BR (1) BR112018069090A2 (zh)
CA (1) CA3018150A1 (zh)
SG (1) SG11201807223UA (zh)
WO (1) WO2017165641A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN112004923A (zh) * 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
US11352646B2 (en) * 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002914A1 (en) * 2003-01-15 2005-01-06 Rosen Michael R. Mesenchymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2006020322A2 (en) * 2004-07-19 2006-02-23 The Trustees Of Columbia University In The City Of New York Assay system for monitoring the effects of genetically engineered cells to alter function of a syncytium
WO2008141177A1 (en) * 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Methods and compositions for the treatment of sarcoma
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER

Also Published As

Publication number Publication date
WO2017165641A1 (en) 2017-09-28
CN108882705A (zh) 2018-11-23
AU2021290224A1 (en) 2022-01-20
KR20180123052A (ko) 2018-11-14
BR112018069090A2 (pt) 2019-01-29
AU2017238505B2 (en) 2021-09-23
EP3432714A1 (en) 2019-01-30
CA3018150A1 (en) 2017-09-28
EP3432714A4 (en) 2019-11-13
AU2017238505A1 (en) 2018-09-06
US20200171067A1 (en) 2020-06-04
JP2019509297A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
SG11201807223UA (en) CANCER TREATMENT BASED ON DELIVERY OF OLIGOES VIA GAP JUNCTIONS FROM HUMAN MESENCHYMAL STEM CELLS (hMSC)
SG11201807187XA (en) Binding members to pd-l1
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809554VA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201906223TA (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201901841TA (en) Targeting ligands
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201809688RA (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201900361RA (en) Methods of treating prostate cancer
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones